In vitro evaluation of a novel hemodynamically optimized trileaflet polymeric prosthetic heart valve

Thomas E. Claiborne, Jawaad Sheriff, Maximilian Kuetting, Ulrich Steinseifer, Marvin J Slepian, Danny Bluestein

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Calcific aortic valve disease is the most common and life threatening form of valvular heart disease, characterized by stenosis and regurgitation, which is currently treated at the symptomatic end-stages via open-heart surgical replacement of the diseased valve with, typically, either a xenograft tissue valve or a pyrolytic carbon mechanical heart valve. These options offer the clinician a choice between structural valve deterioration and chronic anticoagulant therapy, respectively, effectively replacing one disease with another. Polymeric prosthetic heart valves (PHV) offer the promise of reducing or eliminating these complications, and they may be better suited for the new transcatheter aortic valve replacement (TAVR) procedure, which currently utilizes tissue valves. New evidence indicates that the latter may incur damage during implantation. Polymer PHVs may also be incorporated into pulsatile circulatory support devices such as total artificial heart and ventricular assist devices that currently employ mechanical PHVs. Development of polymer PHVs, however, has been slow due to the lack of sufficiently durable and biocompatible polymers. We have designed a new trileaflet polymer PHV for surgical implantation employing a novel polymer - xSIBS - that offers superior bio-stability and durability. The design of this polymer PHV was optimized for reduced stresses, improved hemodynamic performance, and reduced thrombogenicity using our device thrombogenicity emulation (DTE) methodology, the results of which have been published separately. Here we present our new design, prototype fabrication methods, hydrodynamics performance testing, and platelet activation measurements performed in the optimized valve prototype and compare it to the performance of a gold standard tissue valve. The hydrodynamic performance of the two valves was comparable in all measures, with a certain advantage to our valve during regurgitation. There was no significant difference between the platelet activation rates of our polymer valve and the tissue valve, indicating that similar to the latter, its recipients may not require anticoagulation. This work proves the feasibility of our optimized polymer PHV design and brings polymeric valves closer to clinical viability.

Original languageEnglish (US)
Article number021019
JournalJournal of Biomechanical Engineering
Volume135
Issue number2
DOIs
StatePublished - 2013

Fingerprint

Heart valve prostheses
Heart Valves
Polymers
Tissue
Heart-Assist Devices
Platelet Activation
Hydrodynamics
Platelets
Chemical activation
Artificial heart
Artificial Heart
Equipment and Supplies
Aortic Diseases
Heart Valve Diseases
In Vitro Techniques
Hemodynamics
Aortic Valve
Heterografts
Anticoagulants
Deterioration

Keywords

  • DTE
  • finite element analysis
  • hydrodynamics
  • platelet activation
  • xSIBS

ASJC Scopus subject areas

  • Biomedical Engineering
  • Physiology (medical)

Cite this

In vitro evaluation of a novel hemodynamically optimized trileaflet polymeric prosthetic heart valve. / Claiborne, Thomas E.; Sheriff, Jawaad; Kuetting, Maximilian; Steinseifer, Ulrich; Slepian, Marvin J; Bluestein, Danny.

In: Journal of Biomechanical Engineering, Vol. 135, No. 2, 021019, 2013.

Research output: Contribution to journalArticle

Claiborne, Thomas E. ; Sheriff, Jawaad ; Kuetting, Maximilian ; Steinseifer, Ulrich ; Slepian, Marvin J ; Bluestein, Danny. / In vitro evaluation of a novel hemodynamically optimized trileaflet polymeric prosthetic heart valve. In: Journal of Biomechanical Engineering. 2013 ; Vol. 135, No. 2.
@article{a06c0fe84359435dbfcbcfa36ab4d3d7,
title = "In vitro evaluation of a novel hemodynamically optimized trileaflet polymeric prosthetic heart valve",
abstract = "Calcific aortic valve disease is the most common and life threatening form of valvular heart disease, characterized by stenosis and regurgitation, which is currently treated at the symptomatic end-stages via open-heart surgical replacement of the diseased valve with, typically, either a xenograft tissue valve or a pyrolytic carbon mechanical heart valve. These options offer the clinician a choice between structural valve deterioration and chronic anticoagulant therapy, respectively, effectively replacing one disease with another. Polymeric prosthetic heart valves (PHV) offer the promise of reducing or eliminating these complications, and they may be better suited for the new transcatheter aortic valve replacement (TAVR) procedure, which currently utilizes tissue valves. New evidence indicates that the latter may incur damage during implantation. Polymer PHVs may also be incorporated into pulsatile circulatory support devices such as total artificial heart and ventricular assist devices that currently employ mechanical PHVs. Development of polymer PHVs, however, has been slow due to the lack of sufficiently durable and biocompatible polymers. We have designed a new trileaflet polymer PHV for surgical implantation employing a novel polymer - xSIBS - that offers superior bio-stability and durability. The design of this polymer PHV was optimized for reduced stresses, improved hemodynamic performance, and reduced thrombogenicity using our device thrombogenicity emulation (DTE) methodology, the results of which have been published separately. Here we present our new design, prototype fabrication methods, hydrodynamics performance testing, and platelet activation measurements performed in the optimized valve prototype and compare it to the performance of a gold standard tissue valve. The hydrodynamic performance of the two valves was comparable in all measures, with a certain advantage to our valve during regurgitation. There was no significant difference between the platelet activation rates of our polymer valve and the tissue valve, indicating that similar to the latter, its recipients may not require anticoagulation. This work proves the feasibility of our optimized polymer PHV design and brings polymeric valves closer to clinical viability.",
keywords = "DTE, finite element analysis, hydrodynamics, platelet activation, xSIBS",
author = "Claiborne, {Thomas E.} and Jawaad Sheriff and Maximilian Kuetting and Ulrich Steinseifer and Slepian, {Marvin J} and Danny Bluestein",
year = "2013",
doi = "10.1115/1.4023235",
language = "English (US)",
volume = "135",
journal = "Journal of Biomechanical Engineering",
issn = "0148-0731",
publisher = "American Society of Mechanical Engineers(ASME)",
number = "2",

}

TY - JOUR

T1 - In vitro evaluation of a novel hemodynamically optimized trileaflet polymeric prosthetic heart valve

AU - Claiborne, Thomas E.

AU - Sheriff, Jawaad

AU - Kuetting, Maximilian

AU - Steinseifer, Ulrich

AU - Slepian, Marvin J

AU - Bluestein, Danny

PY - 2013

Y1 - 2013

N2 - Calcific aortic valve disease is the most common and life threatening form of valvular heart disease, characterized by stenosis and regurgitation, which is currently treated at the symptomatic end-stages via open-heart surgical replacement of the diseased valve with, typically, either a xenograft tissue valve or a pyrolytic carbon mechanical heart valve. These options offer the clinician a choice between structural valve deterioration and chronic anticoagulant therapy, respectively, effectively replacing one disease with another. Polymeric prosthetic heart valves (PHV) offer the promise of reducing or eliminating these complications, and they may be better suited for the new transcatheter aortic valve replacement (TAVR) procedure, which currently utilizes tissue valves. New evidence indicates that the latter may incur damage during implantation. Polymer PHVs may also be incorporated into pulsatile circulatory support devices such as total artificial heart and ventricular assist devices that currently employ mechanical PHVs. Development of polymer PHVs, however, has been slow due to the lack of sufficiently durable and biocompatible polymers. We have designed a new trileaflet polymer PHV for surgical implantation employing a novel polymer - xSIBS - that offers superior bio-stability and durability. The design of this polymer PHV was optimized for reduced stresses, improved hemodynamic performance, and reduced thrombogenicity using our device thrombogenicity emulation (DTE) methodology, the results of which have been published separately. Here we present our new design, prototype fabrication methods, hydrodynamics performance testing, and platelet activation measurements performed in the optimized valve prototype and compare it to the performance of a gold standard tissue valve. The hydrodynamic performance of the two valves was comparable in all measures, with a certain advantage to our valve during regurgitation. There was no significant difference between the platelet activation rates of our polymer valve and the tissue valve, indicating that similar to the latter, its recipients may not require anticoagulation. This work proves the feasibility of our optimized polymer PHV design and brings polymeric valves closer to clinical viability.

AB - Calcific aortic valve disease is the most common and life threatening form of valvular heart disease, characterized by stenosis and regurgitation, which is currently treated at the symptomatic end-stages via open-heart surgical replacement of the diseased valve with, typically, either a xenograft tissue valve or a pyrolytic carbon mechanical heart valve. These options offer the clinician a choice between structural valve deterioration and chronic anticoagulant therapy, respectively, effectively replacing one disease with another. Polymeric prosthetic heart valves (PHV) offer the promise of reducing or eliminating these complications, and they may be better suited for the new transcatheter aortic valve replacement (TAVR) procedure, which currently utilizes tissue valves. New evidence indicates that the latter may incur damage during implantation. Polymer PHVs may also be incorporated into pulsatile circulatory support devices such as total artificial heart and ventricular assist devices that currently employ mechanical PHVs. Development of polymer PHVs, however, has been slow due to the lack of sufficiently durable and biocompatible polymers. We have designed a new trileaflet polymer PHV for surgical implantation employing a novel polymer - xSIBS - that offers superior bio-stability and durability. The design of this polymer PHV was optimized for reduced stresses, improved hemodynamic performance, and reduced thrombogenicity using our device thrombogenicity emulation (DTE) methodology, the results of which have been published separately. Here we present our new design, prototype fabrication methods, hydrodynamics performance testing, and platelet activation measurements performed in the optimized valve prototype and compare it to the performance of a gold standard tissue valve. The hydrodynamic performance of the two valves was comparable in all measures, with a certain advantage to our valve during regurgitation. There was no significant difference between the platelet activation rates of our polymer valve and the tissue valve, indicating that similar to the latter, its recipients may not require anticoagulation. This work proves the feasibility of our optimized polymer PHV design and brings polymeric valves closer to clinical viability.

KW - DTE

KW - finite element analysis

KW - hydrodynamics

KW - platelet activation

KW - xSIBS

UR - http://www.scopus.com/inward/record.url?scp=84873686810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873686810&partnerID=8YFLogxK

U2 - 10.1115/1.4023235

DO - 10.1115/1.4023235

M3 - Article

C2 - 23445066

AN - SCOPUS:84873686810

VL - 135

JO - Journal of Biomechanical Engineering

JF - Journal of Biomechanical Engineering

SN - 0148-0731

IS - 2

M1 - 021019

ER -